1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Ms D Conrad
|
|||
b)
|
Position/status
|
SVP,
Human Resources
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature
of the transaction
|
The vesting of Ordinary Shares awarded in 2017 under the Company's
Share Value Plan.
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£0.00
|
11,060
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume Price
|
|
||||
e)
|
Date
of the transaction
|
2020-02-17
|
|||
f)
|
Place
of the transaction
|
N/A
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Ms D Conrad
|
|||
b)
|
Position/status
|
SVP,
Human Resources
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature
of the transaction
|
Following the vesting of Ordinary Shares awarded in 2017 under the
Company's Share Value Plan, Ms Conrad received a cash amount of
£184,000 (less applicable tax withholding) which is equal to
the market value of the number of Ordinary Shares which would
otherwise have been transferred to her.
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£16.619
|
11,060
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume Price
|
|
||||
e)
|
Date
of the transaction
|
2020-02-18
|
|||
f)
|
Place
of the transaction
|
N/A
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Mr J Ford
|
|||
b)
|
Position/status
|
SVP
& General Counsel
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
|||
b)
|
Nature
of the transaction
|
The vesting of ADSs awarded in 2017 under the Company's Share Value
Plan.
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
$0.00
|
6,320
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume Price
|
|
||||
e)
|
Date
of the transaction
|
2020-02-18
|
|||
f)
|
Place
of the transaction
|
N/A
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Mr J Ford
|
|||
b)
|
Position/status
|
SVP
& General Counsel
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
|||
b)
|
Nature
of the transaction
|
The sale of ADSs to meet tax liabilities on the vesting of awards
granted in 2017 under the Company's Share Value
Plan.
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
$43.544
|
2,971
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume Price
|
|
||||
e)
|
Date
of the transaction
|
2020-02-18
|
|||
f)
|
Place
of the transaction
|
New York Stock Exchange (XNYS)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Ms S Jackson
|
|||
b)
|
Position/status
|
SVP,
Global Communications & CEO Office
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature
of the transaction
|
The vesting of Ordinary Shares awarded in 2017 under the Company's
Share Value Plan.
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£0.00
|
13,070
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume Price
|
|
||||
e)
|
Date
of the transaction
|
2020-02-17
|
|||
f)
|
Place
of the transaction
|
N/A
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Ms S Jackson
|
|||
b)
|
Position/status
|
SVP,
Global Communications & CEO Office
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities on the vesting
of awards granted in 2017 under the Company's Share Value
Plan.
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£16.619
|
6,143
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume Price
|
|
||||
e)
|
Date
of the transaction
|
2020-02-17
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Mr D Jackson
|
|||
b)
|
Position/status
|
PCA of
Ms S Jackson (SVP, Global Communications & CEO
Office)
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature
of the transaction
|
The vesting of Ordinary Shares awarded in 2017 under the Company's
Share Value Plan.
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£0.00
|
3,810
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume Price
|
|
||||
e)
|
Date
of the transaction
|
2020-02-17
|
|||
f)
|
Place
of the transaction
|
N/A
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Mr D Jackson
|
|||
b)
|
Position/status
|
PCA of
Ms S Jackson (SVP, Global Communications & CEO
Office)
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities on the vesting
of awards granted in 2017 under the Company's Share Value
Plan.
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£16.619
|
1,791
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume Price
|
|
||||
e)
|
Date
of the transaction
|
2020-02-17
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Mr R Simard
|
|||
b)
|
Position/status
|
President,
Pharmaceuticals Supply Chain
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature
of the transaction
|
The vesting of Ordinary Shares awarded in 2017 under the Company's
Share Value Plan.
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£0.00
|
11,060
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume Price
|
|
||||
e)
|
Date
of the transaction
|
2020-02-17
|
|||
f)
|
Place
of the transaction
|
N/A
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Mr R Simard
|
|||
b)
|
Position/status
|
President,
Pharmaceuticals Supply Chain
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities on the vesting
of awards granted in 2017 under the Company's Share Value
Plan.
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£16.619
|
5,199
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume Price
|
|
||||
e)
|
Date
of the transaction
|
2020-02-17
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Ms D Waterhouse
|
|||
b)
|
Position/status
|
CEO of
ViiV Healthcare
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature
of the transaction
|
The vesting of Ordinary Shares awarded in 2017 under the Company's
Share Value Plan.
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£0.00
|
15,160
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume Price
|
|
||||
e)
|
Date
of the transaction
|
2020-02-17
|
|||
f)
|
Place
of the transaction
|
N/A
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Ms D Waterhouse
|
|||
b)
|
Position/status
|
CEO of
ViiV Healthcare
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities on the vesting
of awards granted in 2017 under the Company's Share Value
Plan.
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£16.619
|
7,126
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume Price
|
|
||||
e)
|
Date
of the transaction
|
2020-02-17
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Ms V Whyte
|
|||
b)
|
Position/status
|
Company
Secretary
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature
of the transaction
|
The vesting of Ordinary Shares awarded in 2017 under the Company's
Share Value Plan.
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£0.00
|
11,060
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume Price
|
|
||||
e)
|
Date
of the transaction
|
2020-02-17
|
|||
f)
|
Place
of the transaction
|
N/A
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Ms V Whyte
|
|||
b)
|
Position/status
|
Company
Secretary
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities on the vesting
of awards granted in 2017 under the Company's Share Value
Plan.
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£16.619
|
5,199
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume Price
|
|
||||
e)
|
Date
of the transaction
|
2020-02-17
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: February
20, 2020
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|